AssayIndex

AX-2025-019151

NAD+ · 100 mg declared · GenScript Biotech Corporation · lot GSP-2503-B3620

PASSVERIFIED
Report ID
AX-2025-019151
Compound
NAD+
Compound class
Non-peptide adjuncts
Supplier
GSP — GenScript Biotech Corporation
Batch / lot
GSP-2503-B3620
Declared label claim
100mg
Laboratory
Janoshik Analytical
Assay date
29 Jul 2025
Submitted
30 Jul 2025
Quarter
2025-Q3
Submitter
fe.novak
Sample provenance
Buyer-sourced
Section 1

Results

Measured against the index acceptance specification for the non-peptide adjuncts class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

ParameterMethodResultUnitIndex spec
PurityRP-HPLC, 30 min gradient, 214 nm99.74% area≥ 97.0PASS
Total impuritiesRP-HPLC, sum of reported peaks0.26% area≤ 3.0PASS
Largest single impurityRP-HPLC — nicotinamide mononucleotide (NMN, −331 Da)0.14% area≤ 1.00PASS
Identity — theoretical monoisotopic masscalculated from molecular formula663.1091DaNOT TESTED
Identity — observed monoisotopic massLC-MS, high resolution (ESI-TOF/QTOF)663.1091DaNOT TESTED
Mass accuracyobserved vs theoretical0.0ppm± 10PASS
Total peptide contentby difference from the gravimetric mass balance90.46%w/wNOT TESTED
Target-compound contenttotal peptide content × purity90.22%w/wNOT TESTED
Gross fill (as weighed)five-place balance, under nitrogen105.08mg100 mg declaredNOT TESTED
Recovered target peptidegross fill × target content94.803mg100 mg claimNOT TESTED
Recovery against label claimrecovered ÷ claim94.8%90.0 – 110.0PASS
Water contentKarl Fischer, coulometric, duplicate9.26%≤ 10.0PASS
Counter-ionno ionisable counter-ion expectedN/Anot applicableNOT TESTED
Residual solvent + inorganic residueestimated — see /methods/residual-solvents-q3c/0.28%NOT TESTED
Endotoxinnot ordered on this submissionnot determined≤ 5.0NOT TESTED
Sterilitynot ordered on this submissionnot determinedno growthNOT TESTED
Appearancevisual, diffuse light, black and white backgroundWhite lyophilised cake, intactwhite to off-white intact cakePASS
Reconstitution clarityreconstituted per submitter procedureClear after 90 s gentle swirling, no particulatesclear, no visible particulatesPASS
pH (reconstituted, 1 mg/mL)potentiometric, two-point calibration6.122.5 – 8.0PASS
Retention time (observed)RP-HPLC, 30 min gradient4.19min4.16 ± 0.25 (normalised)PASS
Peak asymmetry (10 % height)Ph. Eur. 2.2.460.900.80 – 1.50PASS
Plate count, main peakN = 5.54 (t/w½)²56,591≥ 20,000PASS
Resolution to nearest impurityvs α-NAD anomer2.49no index criterionREPORTED
Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

06900138002070027600 NAD+4.19 min · 99.74 % 3.77 same trace · ×200 vertical expansion, baseline-corrected · main peak off-scale reporting threshold 0.05 % area 05101520253035 Retention time (min) Response (mAU)
Figure 1. RP-HPLC trace, 30 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 56,591, and skew follows the reported asymmetry factor of 0.90. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.14 % impurity against a 99.74 % main peak is a line two pixels tall; the main peak runs off-scale there by design.
#PeakRTArea (µV·s)% areaΔ mass (Da)
1NAD+ — main peak4.194,847,67399.74
2nicotinamide mononucleotide (NMN, −331 Da)3.776,8040.14-331.058
3nicotinamide (−541 Da)3.512,9160.06-541.052
4α-NAD anomer4.371,9440.040.000
5ADP-ribose (−121 Da)3.939720.02-121.040
Closure check — purity + Σ impurities 100.00CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 663.1091 Da, computed from C21H27N7O14P2. All ppm figures on this site are against monoisotopic values — see why that matters.

0255075100275350425500575650725 [M+1H]1+664.12[M+2H]2+332.56 m/z Relative abundance (%)
Figure 2. ESI charge-state envelope, high-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 663.1091 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.
ChargeTheoretical m/zObserved m/zΔ m/zRel. abundance (%)
2+332.5618332.5618-0.000057.2
1+664.1164664.11640.0000100.0
Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

ComponentDetermination%w/w of cake
WaterKarl Fischer9.26
Counter-ionnone expected0.00
Residual solvent + inorganic residueestimated0.28
Total peptide contentby difference90.46
Total100.00 CLOSES

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

FigureSupplier COAThis reportIndex note
Purity (% area)99.8399.74divergence +0.06 pp vs batch median
Total impurities (% area)0.170.26
Largest single impurity (% area)0.060.14
Water (%)not stated9.26
Counter-ion (%)4.5N/A
Peptide content (%w/w)91.490.46
Endotoxin (EU/mg)0.43not determined
Method stated on certificateYEScolumn, gradient and wavelength given
Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance
Buyer-sourced
Evidentiary weight
Strongest available evidence in this index.
Chain of custody
Retail purchase → submitter (−20 °C, 5 d) → laboratory (courier, dry ice, 10 d) → assay.
Assay date
29 Jul 2025
Submitted to the index
30 Jul 2025
Laboratory
Janoshik Analytical, Ostrava, Czechia
Method basis
30 min gradient · high-resolution MS
Verification status
VERIFIED
Section 6

Annotations 2

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

ms_confirm
Two instruments or it is not confirmed, and this record is one instrument. It is a good one instrument, and the index records it as confirmed rather than corroborated for that reason.
multiple_compare
Restricting every supplier comparison to buyer-sourced records is the sensitivity analysis the scorecards publish. On the current dataset it changes no ordering that was not already inside measurement noise.
Section 7

Related records

Same batch — lot GSP-2503-B3620 n=3

ReportLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2025-019149GSP-2503-B3620Janoshik2025-Q399.839.9192.2Buyer-sourced0PASS
AX-2025-019150GSP-2503-B3620Medutest2025-Q399.779.62Buyer-sourced0PASS
Other recent NAD+ records in the index.
ReportSupplierLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2026-041208WWBWWB-2601-V1583VendorInvestigate2026-Q299.4711.38100.9Buyer-sourced0FAIL
AX-2026-041209WWBWWB-2601-V1583Nordanalyt2026-Q299.4711.40106.7Buyer-sourced0FAIL
AX-2026-041210WWBWWB-2601-V1583Nordanalyt2026-Q299.6611.0191.9Buyer-sourced0FAIL
AX-2026-041211WWBWWB-2601-V1583Janoshik2026-Q299.7210.9493.5Buyer-sourced0FAIL
AX-2026-041213WWBWWB-2601-V1583VendorInvestigate2026-Q299.3311.41Buyer-sourced0FAIL
AX-2026-041212WWBWWB-2601-V1583Janoshik2026-Q299.9310.3688.5Laboratory-retained1FAIL
AX-2025-019628TFCTFC-2505-C1792Janoshik2025-Q399.7211.1992.6Buyer-sourced0FAIL
AX-2025-019134GSPGSP-2507-A3926Janoshik2025-Q398.8411.68Buyer-sourced0FAIL
Other recent GSP records in the index.
ReportCompoundLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2026-041831SurvodutideGSP-2603-E3156Kestrel2026-Q399.915.5093.2Buyer-sourced0PASS
AX-2026-041836SurvodutideGSP-2603-E3156Janoshik2026-Q398.655.3490.3Buyer-sourced0PASS
AX-2026-041837SurvodutideGSP-2603-E3156Janoshik2026-Q398.335.37Buyer-sourced0PASS
AX-2026-041833SurvodutideGSP-2603-E3156Janoshik2026-Q398.084.9199.3Buyer-sourced0PASS
AX-2026-041832SurvodutideGSP-2603-E3156VendorInvestigate2026-Q398.015.1499.5Buyer-sourced0PASS
AX-2026-041835SurvodutideGSP-2603-E3156Nordanalyt2026-Q398.345.7489.0Buyer-sourced1MARGINAL
AX-2026-041834SurvodutideGSP-2603-E3156VendorInvestigate2026-Q397.925.95Buyer-sourced0PASS
AX-2026-041838SurvodutideGSP-2603-E3156PeptideMeter2026-Q398.305.01102.4Buyer-sourced0PASS